Hormone therapy instead of surgery for early breast changes
Part of Cancer clinical trials.
This study tests whether hormone therapy can safely treat certain non-invasive breast conditions (like DCIS) instead of surgery. It may offer an option to avoid surgery if the condition is low-risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 35 or older.
- You have a biopsy showing atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS).
- Your biopsy shows the cells are estrogen receptor positive and HER2 negative.
- If your biopsy is high grade, the Ki-67 index must be 20% or less.
- You have no prior breast cancer and no current invasive breast cancer.
- You are not pregnant and not a BRCA1/2 mutation carrier.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This Phase 2 study tests whether taking hormone medicine before surgery can change the surgical plan and outcomes for people with extensive ductal carcinoma in situ (DCIS). It is for estrogen-receptor positive DCIS and aims to see how this “neoadjuvant” approach affects treatment decisions.
This study is looking at whether it is safe for younger women who have had surgery for a very early-stage, low-risk breast condition called DCIS to skip radiation therapy. The goal is to see if they can avoid the side effects of radiation without the cancer coming back.
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
This trial is testing a lower dose of treatment for women with small, early-stage breast cancer that is hormone-positive and has not spread to lymph nodes. The goal is to find out if it can be as effective as the standard treatment with fewer side effects.
Hear when a new Ductal Carcinoma in Situ of the Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.